Professional
Added to YB: 2025-11-03
Pitch date: 2025-09-30
ZBIO [neutral]
Zenas BioPharma, Inc.
+83.67%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Market Cap
$1.3B
Pitch Price
$22.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.33
P/E
-5.69
EV/Sales
66.60
Sector
Biotechnology
Category
growth
Show full summary:
Meridian Small Cap Growth Fund Portfolio Holding: Zenas BioPharma, Inc.
ZBIO trimmed position: Clinical-stage biotech focused on autoimmune therapies. Lead drug Obexelimab in Phase 3 trials, potential 2027 approval/launch. Secured $300M non-dilutive financing deal with Royalty Pharma to fund trials & commercialization. Position trimmed on share price appreciation.
Read full article (1 min)